Results 171 to 180 of about 1,499,618 (334)
Molecular Oncology, EarlyView.This study explores salivary RNA for breast cancer (BC) diagnosis, prognosis, and follow‐up. High‐throughput RNA sequencing identified distinct salivary RNA signatures, including novel transcripts, that differentiate BC from healthy controls, characterize histological and molecular subtypes, and indicate lymph node involvement.
Nicholas Rajan +9 more
wiley +1 more source
The impact of the introduction of social welfare schemes in Ireland, (1930s-1950s) [PDF]
The relatively few studies of the Irish social welfare system have focused mainly on the forces behind the introduction of social welfare schemes rather than the impact which these schemes had in demographic and labour market terms.
Cousins, Mel
core +1 more source
La pauvreté chez les enfants des pays riches. Commentaires sur le « Rapport Innocenti ». UNICEF. 2000. A league Table of Child Poverty in Rich Nations . Innocenti Report Card. Issue No. 1. June 2000. United Nations Children's Fund, Innocenti Research Centre, Florence [PDF]
, 2000 Ilona Ostner
openalex +1 more source
Molecular Oncology, EarlyView.A‐to‐I editing of miRNAs, particularly miR‐200b‐3p, contributes to HGSOC progression by enhancing cancer cell proliferation, migration and 3D growth. The edited form is linked to poorer patient survival and the identification of novel molecular targets.
Magdalena Niemira +14 more
wiley +1 more source
Molecular Oncology, EarlyView.This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian +10 more
wiley +1 more source
Relative poverty is associated with increased risk of diabetic ketoacidosis at onset of type 1 diabetes in children. A Swedish national population‐based study in 2014–2019 [PDF]
Johan H. Wersäll +6 more
openalex +1 more source
Molecular Oncology, EarlyView.This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the
Fenneke Zwierenga +8 more
wiley +1 more source